Fastox Pharma

Fastox Pharma is a private Swiss biotechnology company developing products designed to enhance and prolong the effects of botulinum neurotoxin treatments in both aesthetic and therapeutic settings. The company is centered on its LAST platform, which aims to improve botulinum toxin performance without altering the core properties of the toxin itself. Fastox's lead development work appears to focus on FTP-501 and a related combination approach involving FTP-002/FTP-501 for severe glabellar lines. Publicly available sources indicate the company was founded in 2018, is based in Lausanne, and has been backed by Remora Biotech. Fastox has presented its technology at industry meetings and received recognition at the 2023 IMCAS Innovation Tank.